Table 6 Chi-square analysis exploring various knowledge and respondent variables (phases 1 vs 2; 1 vs 4)

A. PHASES 1 AND 2

S/N

KNOWLEDGE VARIABLES

Phase of Study

KNOWLEDGE LEVELS BASED ON DIFFERENT RESPONDENT VARIABLES

Gender

Age (In years)^b

Class of Study^b

Gender of School

Cervical Cancer Aspects

Sample Question^a

Chi Square (X²)

Males

(%)

Females

(%)

< 15

(%)

= 15 to = 19

(%)

SSS^c

(%)

Male-only

(%)

Female-only

(%)

Mixed

(%)

1

Awareness

Having ever heard of cervical cancer

Phase 1

43.2

35.4

32.9

40.9

45.6

34.3

47.6

38.1

Phase 2

72.6

45.5

57.9

64.4

67.7

50.3

84.7

47.4

X²

244.3

19.76

50.36

201.87

69.18

29.10

251.17

17.15

(p)

* < 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

2

Screening

Pap smear is to be done 2-yearly

Phase 1

11.0

16.8

14.5

13.2

11.9

16.2

9.8

14.3

Phase 2

13.4

17.0

14.5

14.8

15.4

18.3

13.2

14.6

X²

3.25

0.02

0.00

1.84

3.33

0.81

4.00

0.03

(p)

0.07

0.88

1.00

0.18

0.07

0.37

0.05

0.86

3

Vaccine

HPV Vaccine is best given before sexual debut

Phase 1

9.3

16.5

13.0

12.3

11.2

16.1

5.8

14.9

Phase 2

8.9

18.8

15.3

11.5

12.0

20.0

6.7

14.1

X²

0.13

1.59

0.85

0.53

0.19

2.61

0.56

0.22

(p)

0.72

0.21

0.36

0.47

0.67

0.11

0.46

0.64

4

Risk Factors

Early onset of sexual activities

Phase 1

6.5

10.3

7.7

8.8

7.7

10.5

5.5

8.5

Phase 2

5.7

14.2

9.7

8.0

8.3

15.5

4.0

10.1

X²

0.77

5.96

0.92

0.04

0.19

5.87

1.84

1.31

(p)

0.38

0.02*

0.34

0.83

0.67

0.02*

0.18

0.25

5

Symptoms

Bleeding after intercourse

Phase 1

10.0

12.6

13.7

10.7

10.1

12.1

8.3

12.6

Phase 2

8.9

13.8

12.3

10.7

9.4

15.6

5.8

13.5

X²

0.92

0.60

0.33

0.00

0.60

2.62

3.48

0.27

(p)

0.34

0.44

0.57

0.99

0.68

0.11

0.06

0.60

B. PHASES 1 AND 4

1

Awareness

Having ever heard of cervical cancer

Phase 1

46.4

36.7

36.4

42.8

47.1

34.2

49.8

40.5

Phase 4

85.4

61.1

70.0

78.1

77.5

61.5

89.6

72.1

X²

131.34

29.71

12.35

146.26

91.84

28.67

93.79

42.60

(p)

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

2

Screening

Pap smear is to be done 2-yearly

Phase 1

11.4

17.3

17.3

13.3

11.8

14.7

9.2

18.7

Phase 4

40.8

24.6

33.3

35.0

34.5

23.1

43.7

33.0

X²

97.00

3.67

3.57

77.37

61.52

4.43

97.74

8.91

(p)

< 0.01*

0.06

0.06

< 0.01*

< 0.01*

0.04*

< 0.01*

< 0.01*

3

Vaccine

HPV Vaccine is best given before sexual debut

Phase 1

8.2

17.0

14.8

11.7

10.2

15.5

4.7

17.3

Phase 4

42.0

25.4

36.0

36.5

35.6

26.9

41.8

37.6

X²

142.99

4.95

7.07

105.02

79.04

7.66

139.27

19.11

(p)

< 0.01*

0.03*

0.01

< 0.01*

< 0.01*

0.01

< 0.01*

< 0.01*

4

Risk Factors

Early onset of sexual activities

Phase 1

7.0

10.1

8.0

8.0

7.9

9.5

5.7

10.1

Phase 4

57.9

49.6

64.0

55.8

54.4

44.4

65.3

49.6

X²

308.38

121.58

56.80

390.55

229.85

76.93

278.71

97.00

(p)

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

5

Symptoms

Bleeding after intercourse

Phase 1

9.7

11.2

15.6

9.8

10.0

9.7

8.6

13.0

Phase 4

48.6

33.6

44.0

43.5

43.1

31.4

53.1

37.9

X²

167.26

40.13

11.78

191.29

120.10

32.98

150.80

31.27

(p)

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*

< 0.01*